| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | T11; SRBC; LFA-2 |
| Entrez GeneID | 914 |
| clone | 3D1E3 |
| WB Predicted band size | 39.4kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Mouse |
| Immunogen | Purified recombinant fragment of human CD2 (AA: 25-140) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于IFNA5抗体的假设性参考文献示例(请注意，这些文献为虚构示例，实际引用需查询真实数据库)：
---
1. **文献名称**: *"Development of a Monoclonal Antibody Specific for Human IFNA5 and Its Application in Detecting Interferon Expression Profiles"*
**作者**: Smith A, et al.
**摘要**: 本研究开发了一种高特异性抗人IFNA5的单克隆抗体，用于区分IFNA5与其他I型干扰素亚型。通过ELISA和免疫组化验证，该抗体成功应用于病毒感染模型中IFNA5的蛋白表达定位，揭示了其在抗病毒反应中的独特表达模式。
2. **文献名称**: *"IFNA5 Neutralizing Antibody Attenuates Autoimmune Inflammation in a Murine Model"*
**作者**: Chen L, et al.
**摘要**: 文章报道了一种中和性IFNA5抗体在自身免疫性疾病模型中的应用。实验表明，阻断IFNA5可显著减少Th17细胞介导的炎症反应，提示IFNA5可能成为治疗类风湿性关节炎等疾病的潜在靶点。
3. **文献名称**: *"Epitope Mapping of IFNA5 Using Polyclonal Antibodies Reveals Functional Domains"*
**作者**: Tanaka K, et al.
**摘要**: 通过多克隆抗体对IFNA5的表位进行定位分析，发现其C端区域对受体结合至关重要。该研究为设计靶向IFNA5的抗体药物提供了结构生物学依据。
4. **文献名称**: *"Differential Expression of IFNA5 in Tumor Microenvironments Identified by Immunohistochemical Staining"*
**作者**: Müller R, et al.
**摘要**: 利用商业化IFNA5抗体对多种癌症组织进行染色，发现IFNA5在肿瘤相关成纤维细胞中高表达，提示其可能通过调控肿瘤微环境影响免疫治疗效果。
---
**备注**：以上文献为示例性质，实际研究中请通过PubMed、Web of Science等平台检索真实文献(如搜索关键词：IFNA5 antibody, interferon alpha 5 antibody)。若需具体文献协助，建议提供更详细的研究方向。
The interferon alpha 5 (IFNA5) protein is a member of the type I interferon (IFN) family, which plays a critical role in innate immunity against viral infections and tumor surveillance. Encoded by the IFNA5 gene, it shares structural homology with other IFN-α subtypes but exhibits distinct receptor-binding affinities and downstream signaling activities. IFNA5 signals through the IFN-α/β receptor (IFNAR), activating JAK-STAT pathways to induce interferon-stimulated genes (ISGs) that mediate antiviral, antiproliferative, and immunomodulatory effects.
Antibodies targeting IFNA5 are essential tools for studying its expression, function, and regulation in both physiological and pathological contexts. They enable detection of IFNA5 in biological samples (e.g., ELISA, Western blot) and localization in tissues (e.g., immunohistochemistry). Such antibodies are particularly relevant in research on autoimmune diseases (e.g., lupus), viral infections, and cancers, where dysregulated IFN signaling is implicated. Additionally, neutralizing IFNA5 antibodies may have therapeutic potential for mitigating IFN-driven pathologies. Commercial IFNA5 antibodies vary in specificity (monoclonal vs. polyclonal), host species, and applications, requiring validation to avoid cross-reactivity with other IFN-α subtypes. Recent studies also explore IFNA5's unique role in tumor microenvironments and its biomarker potential, underscoring the importance of reliable antibody reagents in advancing IFN-related research.
×
